Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
09/2005
09/06/2005US6939875 Carbocyclic oxy sulfides such as [4-(Biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenoxy]-acetic acid, used to control peroxisome proliferator activated receptors (PPAR), for prophylaxis of metabolic disorders
09/06/2005US6939874 Substituted pyrimidinyl derivatives and methods of use
09/06/2005US6939871 Central nervous system disorders including depression and/or anxiety; 5-HT1 type receptor and/or serotonin reuptake inhibition activity
09/06/2005US6939867 Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents
09/01/2005WO2005080388A1 Viral polymerase inhibitors
09/01/2005WO2005080386A1 Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
09/01/2005WO2005080385A1 Indanol derivative
09/01/2005WO2005080384A2 Benzimidazole derivative and use as aii receptor antagonist
09/01/2005WO2005080382A1 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
09/01/2005WO2005080380A1 Kinase inhibitors
09/01/2005WO2005080379A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists
09/01/2005WO2005080378A1 Fused pyridazine derivatives
09/01/2005WO2005080377A1 COMPOUND HAVING TGF-β INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
09/01/2005WO2005080367A1 Ep2 receptor agonists
09/01/2005WO2005080360A1 Compounds
09/01/2005WO2005080357A2 Oxazole derivatives, preparation and therapeutic use therof
09/01/2005WO2005080346A1 Substituted azole derivatives, compositions, and methods of use
09/01/2005WO2005080344A1 Substituted azole compounds and thereof preparation and application
09/01/2005WO2005080339A1 Sulfonyloxy derivatives
09/01/2005WO2005080334A1 Novel heterocyclic compound
09/01/2005WO2005080330A1 Heteroarylphenylurea derivative
09/01/2005WO2005079802A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5
09/01/2005WO2005079801A1 Pyrimidine compounds as purine receptor antagonist
09/01/2005WO2005079800A1 Pyrimidine compounds as purine receptor antagonist
09/01/2005WO2005079798A1 Pyrimidine derivatives and use thereof as agricultural and horticultural fungicides
09/01/2005WO2005079791A1 Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
09/01/2005WO2005079519A2 Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
09/01/2005WO2005079496A2 Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
09/01/2005WO2005079378A2 Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
09/01/2005WO2005066163A3 Thiophene derivatives as chk 1 inihibitors
09/01/2005WO2005037271A3 Large conductance calcium-activated k channel opener
09/01/2005US20050192325 For therapy of bacterial infections; such as N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide
09/01/2005US20050192316 Aryl aniline beta2 adrenergic receptor agonists
09/01/2005US20050192314 Use of urea derivatives of isoxazoles; c-kit kinase inhibitors; anticancer agents; leukemias such as acute myelogenous leukemia (AML), and chronic myelogenous leukemias (CMLs)
09/01/2005US20050192313 Thio substituted with a hetero multiring group; sleepiness, promotion of wakefulness, Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, attention deficit hyperactivity disorder
09/01/2005US20050192304 Rho-kinase inhibitors
09/01/2005US20050192293 Vanilloid receptor VR1 modulators; pain, inflammation, traumatic injury, autoimmune disease; compounds are pyridine subsituted at 2 position with an amido-, sulfoamido- or thioamide-substituted (N-hetero)aryl ring
09/01/2005US20050192291 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
09/01/2005US20050192287 Substituted benzazoles and methods of their use as inhibitors of Raf kinase
09/01/2005US20050192279 Pyridazinones as antagonists of alpha4 integrins
09/01/2005US20050192277 Histamine-3 receptor antagonists; 4-(2-{2-[(2R)-2-methyl-1-pyrrolidinyl]ethyl}-1-benzofuran-4-yl)benzonitrile; acute myocardial infarction, asthma, psychological disorders, gastrointestinal disorders, inflammation, jet lag, cancer, septic shock, Tourette's syndrome, neurodegenerative disorders
09/01/2005US20050192276 modulators of monocyte chemotactic proteins MCP-1 receptor; inflammatory diseases such as asthma and allergies, autoimmune diseases such as rheumatoid arthritis and atherosclerosis
09/01/2005US20050192275 3-(substituted phenyl)-5-substituted-oxazolidin-2-ones; tuberculosis; e.g. (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]-4-oxo-4-phenylbutanamide
09/01/2005CA2557539A1 Indanol derivative
09/01/2005CA2557537A1 Sulfonyloxy derivatives
09/01/2005CA2556480A1 Pyrimidine derivatives and use thereof as agricultural and horticultural fungicides
09/01/2005CA2555402A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5
09/01/2005CA2555272A1 Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
09/01/2005CA2554894A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists
09/01/2005CA2554774A1 Novel heterocyclic compound
09/01/2005CA2554686A1 Compounds
08/2005
08/31/2005EP1568698A1 Pyrrole-derivatives as factor Xa inhibitors
08/31/2005EP1568367A1 Compounds effecting glucokinase
08/31/2005EP1567532A1 Oxazolidinone and / or isoxazoline derivatives as antibacterial agents
08/31/2005EP1567525A2 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
08/31/2005EP1567523A1 Indolyl derivatives
08/31/2005EP1567521A1 Antibacterial compounds
08/31/2005EP1567520A2 Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
08/31/2005EP1567517A1 Anilinopyrazole derivatives useful for the treatment of diabetes
08/31/2005EP1567503A1 Pyrazole derivatives useful as cox-i inhibitors
08/31/2005EP1567491A2 Compounds for inhibition of hiv infection by blocking hiv entry
08/31/2005EP1567489A1 Pyrrolidin-2-one derivatives as inhibitors of thrombin and factor xa
08/31/2005EP1567486A2 Bis-aryl sulfonamides
08/31/2005EP1478437B1 Acc inhibitors
08/31/2005EP1237875B1 Substituted imidazole neuropeptide y y5 receptor antagonists
08/31/2005EP1140809B1 New biphenyl and biphenyl-analogous compounds as integrin antagonists
08/31/2005CN1662508A Compounds, compositions and methods
08/31/2005CN1662240A Plymorphic forms of phenyl oxazolidinone derivatives
08/31/2005CN1660839A Chemical compounds
08/31/2005CN1660815A Cyclic amine derivatives and their use as drugs
08/31/2005CN1660811A Compound of 1, 4-substituted benzenes and preparing method and application
08/31/2005CN1216874C (Hetero) aryl-substituted heterocyclic enaminones, production thereof and use thereof as herbicides, acaricides and insectivides
08/31/2005CN1216872C Quinazoline derivatives and pharmaceutical applications thereof
08/31/2005CN1216864C Positive modulators of nicotinic receptor agonists
08/30/2005US6936633 Pyrrolidinone derivatives
08/30/2005US6936616 Pyrimidine matrix metalloproteinase inhibitors
08/30/2005US6936613 for treatment of central nervous system diseases and disorders, which are responsive to modulation of the Gamma amminobutyric acid (GABA) receptor complex, and for inducing and maintaining anesthesia, sedation and muscle relaxation
08/30/2005US6936603 Treating autoimmune diseases mediated by cathepsin S
08/30/2005US6936600 Oxidoreductase enzyme inhibitors such as (R)-1-[4-(2-methyl-4-phenyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-pyrimidin-2-yl-ethanol, used as antidiabetic agents
08/30/2005US6936570 herbicides
08/25/2005WO2005077944A1 Pyrimidine derivatives for use as vanilloid receptor ligands and their use in the treatment of pain
08/25/2005WO2005077943A1 1 , 3 - dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes
08/25/2005WO2005077938A1 Vanilloid receptor ligands and their use in treatments
08/25/2005WO2005077932A2 Chemokine receptor antagonists
08/25/2005WO2005077918A1 Pth agonists
08/25/2005WO2005077915A1 Pyridazinones as antagonists of a4 integrins
08/25/2005WO2005077914A1 PYRIDAZINONE UREAS AS ANTAGONISTS OF α4 INTEGRINS
08/25/2005WO2005077900A1 Bicyclic amide derivatives
08/25/2005WO2005077463A2 Ligand for a monoamine receptor or transporter for treating addiction or dependence
08/25/2005WO2005077369A1 Piperidine derivatives useful as ccr3 antagonists
08/25/2005WO2005077344A2 Hydantoin derivatives as inhibitors of cellular necrosis
08/25/2005WO2005021515A3 Inhibitors of phosphodiesterase type-iv
08/25/2005WO2005011601A3 6-menbered heteroaryl compounds for the treatment of neurodegenerative disorders
08/25/2005US20050187390 Bicyclic heteroaryl derivatives
08/25/2005US20050187387 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
08/25/2005US20050187277 Protein tyrosine phosphatase inhibitors; diseases including type I and type II diabetes, cancer, autoimmune diseases, AIDS; imidazole, oxazole and thiazole derivatives; e.g. 4-(4-(2,4-dichloro-phenyl)-2-(2-(3'-methanesulfonyl-biphenyl-4-yl)-(E)-vinyl)-imidazol-1-ylmethyl)-benzoic acid
08/25/2005US20050187274 One pot synthesis of 2-oxazolidinone derivatives
08/25/2005US20050187269 Benzimidazole derivative and use thereof
08/25/2005US20050187266 2-Methyl-2-{3-[({[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl}amino)methyl]phenoxy}propanoic acid; polycystic ovarian syndrome; polycystic obesity; dietetics; hypoglycemic agents; antilipemic and - cholesterol agents; hypertriglyceridemia; insulin resistance; metabolic disorders; PPAR modulators
08/25/2005US20050187261 For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine
1 ... 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 ... 647